Probing single-cell metabolism reveals prognostic value of highly metabolically active circulating stromal cells in prostate cancer
Francesca Rivello, Kinga Matuła, Aigars Piruska, Minke Smits, Niven Mehra, Wilhelm T. S. Huck
Abstract
hm-CTCs with up-regulation of prostate-related genes, and 87% were hm-CStCs with profiles characteristic for cancer-associated fibroblasts, mesenchymal stem cells, and endothelial cells. Kaplan-Meier analysis shows that metastatic prostate cancer patients with more than five hm-cells have a significantly poorer survival probability than those with zero to five hm-cells. Thus, prevalence of hm-cells is a prognosticator of poor outcome in prostate cancer, and a potentially predictive and therapy response biomarker for agents cotargeting stromal components and preventing epithelial-to-mesenchymal transition.
Topics & Concepts
Stromal cellProstate cancerCirculating tumor cellCancer researchMesenchymal stem cellCancer cellProstateCancerPCA3CellCancer stem cellBiomarkerBiologyMedicineMetastasisInternal medicinePathologyGeneticsBiochemistryCancer Cells and MetastasisCancer Genomics and DiagnosticsCancer, Hypoxia, and Metabolism